PRX-102 Given to 1st Patient in US Under Expanded Access Program

PRX-102 Given to 1st Patient in US Under Expanded Access Program

283300

PRX-102 Given to 1st Patient in US Under Expanded Access Program

A first patient has been treated with PRX-102 (pegunigalsidase alfa), an investigational enzyme replacement therapy for Fabry disease that is under review for approval, through an expanded access program (EAP) in the United States. “The initiation of treatment in the first patient enrolled in our EAP is an important milestone for the Fabry disease community and another reflection of our commitment to supporting patients, caregivers and their healthcare providers as they make important decisions about their health and disease management,”…

You must be logged in to read/download the full post.